BioInsights - Key success criteria and factors for delivering scalable cell therapy upstream bioprocesses

Key success criteria and factors for delivering scalable cell therapy upstream bioprocesses

Cell & Gene Therapy Insights 2019; 5(3),399-403.

10.18609/cgti.2019.044

Published: 26 April 2019
Commentary
Gautam Banik

Gautam Banik

Gautam Banik is head of Manufacturing and Process Sciences at Neurona Therapeutics where he is working on the development of a human embryonic cell-derived GABAergic interneuron cell product for the treatment of chronic refractory epilepsy and neuropathic pain. Prior to joining Neurona he was Vice President of Manufacturing and Process Sciences at Cellerant Therapeutics where he developed a myeloid progenitor stem cell product derived from adult donors for the treatment of neutropenia in acute myelogenous leukemia and acute radiation syndrome. Dr Banik also developed an antibody drug conjugate product for the treatment of AML for early phase clinical studies. Prior to Cellerant, Dr Banik worked in the Process Sciences group at Cell Genesys from 1997 to 2008. During this period, Dr Banik held a number of positions with increasing responsibility including leading the development of manufacturing processes and scale up to commercial scale for cell therapy products such as GVAX immunotherapy. He also worked on a number of gene therapy and viral vector products. Dr Banik conducted his post-doctoral research in Biochemical Engineering at the University of Colorado at Boulder and received his PhD in Engineering Sciences from Dartmouth College. Dr Banik is the author or co-author of several publications, patent applications and abstracts.